Alzheimer’s disease is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer’s disease. Hence, microglia are considered a major therapeutic target that could potentially yield effective disease-modifying treatments for Alzheimer’s disease. However, despite the interest in studying microglia as Alzheimer’s disease drug targets, the lack of accurate, consistent, and scalable microglial cellular models hinders drug discovery and development.
Watch this webinar to learn about:
- The emerging role of microglia in the pathogenesis of Alzheimer's disease
- Specifically, how microglia could be used as a therapeutic target to treat the disease
- The validation of bit.bio’s hiPSC-derived ioMicroglia cells as a potential human-based cellular model for Alzheimer's disease research and drug development
